Results 191 to 200 of about 8,055 (251)

GLP‐1 Receptor Agonists and Risk of Skin Cancer in Adults With Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9377-9384, October 2026.
ABSTRACT Aims Existing evidence regarding the association between glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) and risk of melanoma and non‐melanoma skin cancer (NMSC) is inconclusive. This study aimed to assess the association between GLP‐1RA initiation and risks of melanoma and NMSC versus sodium–glucose cotransporter 2 inhibitors (SGLT2is ...
Huilin Tang, Bingyu Zhang, Ying Lu, Ting Zhou, Yiwen Lu, César A. Briceño, Jiali Han, Yong Chen   +7 more
wiley   +1 more source

Starvation-Type Euglycemic Ketoacidosis After Unsupervised Tirzepatide Use in a Non-Obese, Non-Diabetic Woman. [PDF]

Am J Case Rep
Abdelshafey EE, Sewify K, Almutairi A, Elmessery R, Alotaishan S, Al-Gindan YY, Ali Ahmad M, Gomaa W.   +7 more
europepmc   +1 more source

Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study. [PDF]

Front Endocrinol (Lausanne)
Kahkedjian F, Shah J, Kreidieh F.
europepmc   +1 more source

Nanomedicine for the Treatment of Pediatric Type 2 Diabetes: Progress, Challenges, and Translational Perspectives

Advanced Therapeutics, Volume 9, Issue 9, September 2026.
Overview of pharmaceutical nanocarriers in diabetes, illustrating applications of nanotechnology including enhanced drug and targeted drug delivery and nanosensors for glucose monitoring and diagnosis. ABSTRACT Pediatric type 2 diabetes mellitus (T2DM) is rapidly emerging as a critical global health concern, driven largely by rising childhood obesity ...
Nnamdi Ikemefuna Okafor, Bukosi Baloyi, Yahya E. Choonara   +2 more
wiley   +1 more source

Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets. [PDF]

Pharmaceutics
Im S, Lee JY, Kim JE.
europepmc   +1 more source

GLP‐1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri‐Procedural Guidance

Chronic Diseases and Translational Medicine, Volume 12, Issue 3, Page 183-196, September 2026.
Pharmacological mechanisms and physiologic effects of GLP‐1 receptor agonists relevant to peri‐endoscopic risk. ABSTRACT The global increase in obesity, type 2 diabetes mellitus (T2DM), and metabolic dysfunction‐associated steatotic liver disease (MASLD) has led to a higher use of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) among patients ...
Junaid Beig, Jason Ta, Sophie Jones, Emily Scott, Khalid Sofi, Frances Osler, Marije Jansen, Puneet Chhabra   +7 more
wiley   +1 more source

Tirzepatide Regulates Pacemaker Function by Modulating cAMP and Calcium Dynamics in Human Sinoatrial Node Cells. [PDF]

Circulation
Ren L, Belbachir N, Zhang H, Thai PN, Huang R, Zhu W, Wu X, Xie M, Gao J, Kim HY, Liu T, Sun J, Ghazizadeh Z, Navedo MF, Wu JC.   +14 more
europepmc   +1 more source

Weight Loss‐Dependent Changes in Body Composition and Bone Health in People With Obesity and Type 1 Diabetes Treated With Liraglutide, Semaglutide, or Tirzepatide

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 6, September 2026.
ABSTRACT Aims This study examined changes in body composition and bone mineral density (BMD) over 12 months in people with obesity and type 1 diabetes (T1D) treated with a GLP‐1 receptor agonist alone (GLP‐1RA) or a dual glucose‐dependent insulinotropic polypeptide (GIP/GLP‐1RA).
Ebaa Al Ozairi, Mohammad Irshad, Jumana Alkandri, Anant Mashankar, Stuart R. Gray, Carel W. le Roux   +5 more
wiley   +1 more source

Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Heart Failure Outcomes: A Scoping Review of Contemporary Randomized Controlled Trials. [PDF]

Cureus
Patel J, Patel D, Pino M.
europepmc   +1 more source